In this regard, CTCL patients were observed to have downregulated expression of CD30 after brentuximab treatment; a similar phenomenon also occurred with C-C chemokine receptor type 4 (CCR4) following mogamulizumab treatment (10, 11). The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.